InsidersTradesSigma
SC
Savaria Corporation Stock: price and management transactions · Canada · SEDI
Follow the Savaria Corporation share price and the full directors' dealings record of the company, a listed equity based in Canada. Shares are quoted on CA CA, under the authority of SEDI. Operating in the Healthcare & Pharma sector, Savaria Corporation has logged 13 reports. Market capitalisation: €2.2bn. The latest transaction was reported on 29 June 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Drutz, Peter Allen. Every trade is openly available.
13
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Savaria Corporation Buy (bullish), based on 8 analysts. Average price target: CA$35.00.
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 10,411 of 26,179 companies
57.2
score / 100
Value52
Quality63
FCF yld5.3%
Earn yld3.2%
EV/EBITDA15.1x
ROE13%
Gross mgn39%
Net mgn7.5%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 June 2026
Declarations13 total
▲
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)Executives
5,000 shares@ CA$28.9220.0043% mcap48.8% of flowCommon SharesTSXSEDI:4741242
Ideal exit: 23 Mar 2027 (T+270)
◇
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)Executives
5,000 shares@ CA$15.180.0022% mcap25.6% of flowCommon SharesTSXSEDI:4741241
◇
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)Executives
5,000 shares@ CA$15.180.0022% mcap25.6% of flowOptionsTSXSEDI:4741240
▲
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of IssuerExecutives
200 shares@ CA$29.500.0002% mcap0.2% of flowCommon SharesTSXSEDI:4738718
Ideal exit: 16 Mar 2027 (T+270)
▲
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of IssuerExecutives
7,500 shares@ CA$29.530.0065% mcap7.2% of flowCommon SharesTSXSEDI:4738266
Ideal exit: 13 Mar 2027 (T+270)
▲
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of IssuerExecutives
95,000 shares@ CA$29.690.084% mcap100.0% of flowCommon SharesTSXSEDI:4735354
Ideal exit: 7 Mar 2027 (T+270)
9,736 shares@ CA$29.000.0084% mcap21.2% of flowCommon SharesTSXSEDI:4731109
Ideal exit: 3 Mar 2027 (T+270)
15,264 shares@ CA$27.36710.016% mcap40.0% of flowCommon SharesTSXSEDI:4720382
Ideal exit: 7 Feb 2027 (T+270)
25,000 shares@ CA$12.52830.012% mcap30.0% of flowCommon SharesTSXSEDI:4720381
25,000 shares@ CA$12.52830.012% mcap30.0% of flowOptionsTSXSEDI:4720380
25,000 shares@ CA$27.58590.026% mcap52.4% of flowCommon SharesTSXSEDI:4720378
Ideal exit: 6 Feb 2027 (T+270)
25,000 shares@ CA$12.51460.012% mcap23.8% of flowCommon SharesTSXSEDI:4720377
25,000 shares@ CA$12.51460.012% mcap23.8% of flowOptionsTSXSEDI:4720376
13 of 13 declarations
About Savaria Corporation
Savaria Corporation (TSX/TSXV: SIS) is a Canadian company listed on the Toronto Stock Exchange, focused on accessibility and mobility solutions. Headquartered in Laval, Quebec, Canada, Savaria designs, manufactures and sells a broad portfolio of products for private homes, healthcare facilities, and certain public spaces. The company is positioned as a global niche leader, with structural demand supported by aging demographics, the desire to age in place, and rising accessibility requirements across buildings and care environments. ([corp.savaria.com](https://corp.savaria.com/?lang=en&utm_source=openai)) Founded in 1979, Savaria was acquired in 1989 by Marcel Bourassa, now Executive Chairman, who helped transform a small local business into an international platform. Over time, the company expanded through a selective acquisition strategy that added specialist brands and capabilities in residential and commercial elevators, lifting platforms, stairlifts, patient lifts, and long-term care products. This history has shaped Savaria into a more diversified industrial healthcare-accessibility group rather than a single-product manufacturer. ([savaria.com](https://www.savaria.com/our-company?lang=en&utm_source=openai)) Savaria operates through two reportable segments: Accessibility and Patient Care. Accessibility includes home elevators, commercial lifts, stairlifts, wheelchair lifts, vehicle conversion solutions, and related mobility equipment. Patient Care covers medical beds, therapeutic surfaces, and other care-focused products. The company supports these businesses with an international manufacturing and distribution footprint, with production and operations across North America, Europe, and Asia, allowing it to serve local markets while tailoring offerings to regional requirements. ([corp.savaria.com](https://corp.savaria.com/?lang=en&utm_source=openai)) From a competitive standpoint, Savaria benefits from one of the broader product ranges in the sector, an established dealer network, and a reputation for reliability and product quality. Its scale gives it exposure to both residential and institutional end markets, while its geographically distributed facilities help reduce customer lead times and support localized engineering and customization. In a fragmented market, this combination of breadth, brand recognition, and manufacturing flexibility is an important competitive advantage. ([corp.savaria.com](https://corp.savaria.com/?lang=en&utm_source=openai)) Recent developments indicate continued operational momentum. In 2025, Savaria reported record full-year 2024 results, followed by improved second-quarter 2025 results, with growth led by Accessibility and supported by an acquisition completed during the quarter. In March 2026, the company reported fiscal 2025 annual revenue of C$913.5 million and stronger adjusted EBITDA trends, and in September 2025 it increased its monthly dividend. For investors, Savaria combines exposure to a resilient long-term healthcare-accessibility theme with recurring cash-return discipline and ongoing operational execution. ([savaria.com](https://www.savaria.com/our-company/investors?node=Q2-2025-results&utm_source=openai))
